Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
Sumitomo Dainippon Pharma’s investigational anticancer agent napabucasin failed to meet its primary endpoints in a PIII multinational clinical trial for colorectal cancer, according to the topline results announced by the company on February 9. The trial, named the CanStem303C study,…
To read the full story
Related Article
- Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
March 8, 2021
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- Sumitomo Dainippon’s Napabucasin Flops in Pancreatic Cancer Trial
July 3, 2019
- Napabucasin PIII Colorectal Cancer Trial to Continue: Sumitomo Dainippon
June 10, 2019
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…